HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allegra Ad State Law Portrayal Misleading When Applied To Benadryl – W-L

This article was originally published in The Tan Sheet

Executive Summary

A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports

You may also be interested in...



Claritin Pollen Chaser Bus Campaign Drives Home Antihistamine Safety

Schering-Plough's Pollen Chaser marketing campaign for Claritin, breaking in time for the spring allergy season, focuses on the antihistamine's non-sedating characteristics

Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches

FDA likely will face a legal challenge regardless of whether the agency decides to implement mandated Rx-to-OTC switches or chooses a more indirect policy yielding similar results, according to comments made by Aventis and Pfizer executives

OTC/Rx Sodium Phosphate Laxative Claim Dispute Referred By NAD

InKline Pharmaceuticals, which sells Rx sodium phosphate tablets, has declined to participate in the NAD self-regulatory forum, maintaining NAD is not the proper authority to review its marketing claims

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel